July 18, 2019

News

FDA Approves First Targeted Therapy for Metastatic Bladder Cancer
SPT Staff
The FDA granted accelerated approval to erdafitinib for adult patients with locally advanced or metastatic bladder cancer.
FDA Approves Novel Intravenous Immune Globulin Treatment
SPT Staff
The FDA granted approval to ADMA Biologics’ intravenous immune globulin drug product for use in the treatment of primary humoral immunodeficiency disease.
Immunotherapy Regimen Gets FDA Approval for Extensive Small Cell Lung Cancer
SPT Staff
Atezolizumab (Tecentriq) approved in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer.
Janssen Seeks Approval for Darzalex Combo to Treat Multiple Myeloma
Jennifer Barrett, Associate Editor
Daratumumab (Darzalex) in combination with lenalidomide and dexamethasone under evalution as a treatment for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
FDA Approves Immunotherapy Combination for Breast Cancer
Jennifer Nessel, Assistant Editor
Combination regimen of atezolizumab and chemotherapy Abraxane approved for adults with unresectable locally-advanced or metastatic triple-negative breast cancer.
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us